ChemImage Wins Defense Contract for Production of Threat Detection Technology
ChemImage Corporation was recently awarded a $17-million contract by the U.S. Army Space & Missile Defense Command for the implementation of its real-time sensor technology that will be used in the field to detect explosive threats.
The work to be performed in this contract will include the fabrication and delivery of multiple sensors to the U.S. Army, as well as product testing, soldier training and field support. General Dynamics Armament and Technical Products has teamed with ChemImage to support this effort.
“This is a landmark event for our company,” said Patrick Treado, Ph.D., Founder & Chief Technology Officer at ChemImage. “We’re honored that ChemImage technology will be used to help keep U.S. soldiers and our country safe.”
In addition to this contract award, ChemImage was one of 25 companies recently identified as a participant of the U.S. Army Small Business Innovation Research (SBIR) 2011 Commercialization Pilot Program (CPP) to help transition similar technology from research and development to commercial use.
For more information on ChemImage’s threat detection capabilities, click here.
About ChemImage Corporation
ChemImage Corporation is a Pittsburgh based company committed to making the world healthier and safer through dramatic advancements in chemical imaging technology. The company combines proprietary, state-of-the-art imaging sensors, algorithms and analytical software to solve the world's most challenging health and safety issues.
ChemImage seeks to provide an Awareness of Things™ (AoT™) to a global audience, using the company's innovation platforms to provide people with unprecedented levels of vision, information and situational knowledge about their surroundings in their everyday lives. To accomplish this goal, the firm develops technologies for chemical and biological applications across many global industries; including life sciences, bio-medical, security, threat detection, anatomic pathology, forensics and diagnostics.
For more information, contact ChemImage.